GenomeQuest, a global provider of large-scale genomic software applications, announced the availability of the industry's first clinical decision-support system for whole-genome diagnostics.
Used to analyze and report information about variations and changes in genes and proteins to improve disease treatment, the GQ-DxSM product will launch immediately for the scientific and clinical communities seeking practical and efficient ways to translate advances from whole-genome sequencing into clinical application.
"With whole-genome sequencing advancing to practical use, we see that the next roadblock is the effective clinical application of the emerging discoveries and vast amounts of data," said Richard Resnick, GenomeQuest's CEO. "GQ-Dx makes use of the aligned advancements in sequencing, bioinformatics, computing, and medicine to deliver whole-genome molecular diagnostics. Just as the industry has been able to reduce sequencing time and cost, GenomeQuest has addressed analysis time and cost so that researchers can finally take data from the bench and apply it at the bedside."
GQ-Dx runs on genome center-scale, secure, cloud-based computing infrastructure housed and maintained by GenomeQuest. This service-based software option requires no capital or infrastructure investment and offers simple administration for diagnostic organizations. Optionally, customers can install GQ-Dx in their data center behind their firewall. Diagnostics users access all processing, reporting and research features via the Internet from their desktop or smart device.
Approximately $5 trillion is spent annually on global health care, about 65 percent of therapy decisions are based on the results of diagnostics tests, and molecular diagnostics are the fastest-growing segment of the diagnostics market. Major diagnostic advances enabled by whole-genome sequencing immediately supported by GQ-Dx include consolidation of existing molecular tests, pharmacogenomic screening, and a new generation of discoveries in diagnosing complex, multi-gene disorders.
Designed for academic research laboratories, diagnostics labs, IVD manufacturers, and pharmaceutical companion diagnostic groups, GQ-Dx is already being used in clinical research. In collaboration with GenomeQuest, pathologists at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, are developing "clinical grade" annotation methods and databases for cancer diagnoses. In February, GenomeQuest created a GeneTests-based diagnostic panel that generates a report on disease susceptibility, diagnosis, and treatment on more than 2,000 disorders from a single, whole-genome sequence of a patient.
GenomeQuest is a global provider of large-scale genomic software applications. Based on a whole/multi-genome hosting platform, the company's products include GQ-IP for global research of genomic sequence intellectual property, GQ-Dx, the industry's first clinical decision-support system for whole-genome diagnostics, and GQ-Research, a research platform for teams to store, manage, and analyze genomic information at whole/multi-genome scale. GenomeQuest serves major pharmaceutical companies, global agriculture firms, biotech firms, IP legal groups, genome centers, academic research centers, diagnostic companies and labs, and universities around the world.
((Comments on this story may be sent to newsdesk@closeupmedia.com))
No comments:
Post a Comment